Option chain shows key data for Bayer's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bayer.

Bayer (OTC:BAYZF) Stock, Option Chain

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.

Large Cap

News

Health Care

Legal

General

BAYRY

BAYZF

Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company&#39;s stance that product is safe.

Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer

Bayer US-Roundup-Ready-to-use-Weed-And-Grass-Killer-Iii-III-Main-5200210-Xxl_0

Media

Pennsylvania judge cuts Bayer&#39;s $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation.

Judge Slashes Bayer&#39;s Massive $2B Roundup Verdict To $400M

Crypto hack Photo by Bits And Splits on Shutterstock

ABBV

ACAD

REGN

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans&#39; Health Information Stolen In Data Breach In February

Bayer AG

Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby

DZ BANK AG analyst Peter Spengler maintained a Buy rating on Bayer (0P6S – Research Report) today. The company's shares closed yesterday at €19.25....

DZ BANK AG Remains a Buy on Bayer (0P6S)

OneMedNet Corporation (ONMD) announced its collaboration with Bayer's (BAYRY) AI Innovation Platform. By joining AIIP, the partnership aims to empo...

OneMedNet announces collaboration with Bayer's AI Innovation Platform

Bayer's Stock Hits 2-Decade Low: Why It Is A Buy Again

Regeneron: Recent Bear Run May Be Justified -- Pharma Faces A Testing 2025

Regeneron: Recent Bear Run May Be Justified - Pharma Faces A Testing 2025

UBS analyst Geoff Haire maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The company's shares clo...

Bayer (0P6S) Receives a Hold from UBS

BridgeBio Pharma (BBIO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing aut...

Comments

Bayer

Bayer (BAYZF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga